Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Inclusion criteria

• Patients aged over 18 years old.
• Patients have been diagnosed with metastatic triple-negative breast cancer (mTNBC). ER, PgR, and HER2 status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections. ER-negative and PgR-negative status was defined as≤1% staining in the nuclei by IHC. HER2-negative status was defined by IHC staining 0 to 1+ or fluorescence in situ hybridization ratio <2.0 if IHC 2+ or IHC not performed.
• The metastatic disease was confirmed by clinical, imaging, histological, or cytological measures, including unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
• Patients who have received at least 1 prior regimen in the metastatic setting.
• Plan to receive or has received sacituzumab govitecan monotherapy or chemotherapy of the physician's choice.
• Available medical history.
• All patients can provide an informed consent before enrolment and data collection.

Exclusion criteria

• If participating in any controlled clinical trial, the subject cannot take part in this study.
• HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.
• Pregnancy and lactation.
• Severe hepatic impairment.